AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00770471
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00770471
Drug: veliparib
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01981811
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00560482
Drug: ABR-215050, tasquinimod
DrugBank: Tasquinimod (DB05861)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)
Trial: NCT01563913
Drug: Docosahexaenoic Acid (DHA)
RxNorm normalized name: Docosahexaenoic Acid (DHA)
DrugBank: Doconexent (DB03756)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
Trial: NCT04388124
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: vascular assesment Clinical exam urinary analysis blood results natriuresis and measured glomerular filtration rate
Trial: NCT01817166
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
Trial: NCT01374971
Drug: Certolizumab Pegol (CZP)
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
Trial: NCT00005069
Drug: arsenic trioxide
RxNorm normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03942887
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.
Trial: NCT03942887
Drug: endoxan
RxNorm normalized name: Endoxana
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.
Trial: NCT03942887
Drug: Methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.
Trial: NCT03058471
Drug: NSAID
RxNorm normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: this arm will be given NSAID to the tolerable full dose with pantoprazole
Trial: NCT00003032
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003032
Drug: mitoxantrone hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003032
Drug: tamoxifen citrate
RxNorm normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00078845
Drug: Amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg three times a week.
Trial: NCT00435461
Drug: Fluticasone furoate and fexofenadine
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate and fexofenadine
Trial: NCT04462822
Drug: Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT01089010
Drug: 250 mg CK-2017357
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 250 mg CK-2017357 in capsules administered as a single oral dose.
Trial: NCT01089010
Drug: 500 mg CK-2017357
RxNorm normalized name: chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg CK-2017357 in capsules administered as a single oral dose.
Trial: NCT02959918
Drug: SEL-212
RxNorm normalized name: SEL-212
DrugBank: Pegadricase (DB15129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEL-212, biologic
Trial: NCT02959918
Drug: SEL-037
RxNorm normalized name: SEL-037
DrugBank: Pegadricase (DB15129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SEL-037, biologic
Trial: NCT02970539
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab will be administered by iv infusion and supplied as a solution at a concentration of 10 mg/mL
Trial: NCT04673955
Drug: Encorafenib
RxNorm normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Observation of real-life treatment with encorafenib and cetuximab
Trial: NCT04673955
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Observation of real-life treatment with encorafenib and cetuximab
Trial: NCT02023112
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capsule
Trial: NCT01277913
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU once daily for 12 months
Trial: NCT01277913
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 IU once daily for 12 months
Trial: NCT02910219
Drug: Crofelemer
RxNorm normalized name: Crofelemer
DrugBank: Crofelemer (DB04941)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
Trial: NCT02055170
Drug: finasteride 5mg oral daily
RxNorm normalized name: finasteride 5 MG
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00708903
Drug: neratinib
RxNorm normalized name: NERATINIB
DrugBank: Neratinib (DB11828)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: HKI-272
Trial: NCT00708903
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03147599
Drug: Coloverin
RxNorm normalized name: Cloverine
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mebeverine hydrochloride 135 mg
Trial: NCT01124799
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg, for 9 days
Trial: NCT01424241
Drug: Sandostatin LAR
RxNorm normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Open label dose escalation of Sandostatin LAR 10 mg, 20 mg, 30 mg, up to 40 mg if necessary.
Trial: NCT01266005
Drug: Clevudine
RxNorm normalized name: clevudine
DrugBank: Clevudine (DB06683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30mg,QD
Trial: NCT01266005
Drug: Entecavir
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5mg QD
Trial: NCT00551525
Drug: Samarium 153
RxNorm normalized name: Samarium 153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Samarium 153 lexidronam dose 2.0 mCi/kg by IV injection one time within 2 weeks (+/- 3days) after registration.
Trial: NCT00442026
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
Trial: NCT00442026
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
Trial: NCT00442026
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
Trial: NCT00287521
Drug: Latanoprost, 0.005% (Xalatan)
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop in the study eye(s) once daily for 28 days
Trial: NCT00287521
Drug: Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One drop in the study eye(s) once daily for 28 days
Trial: NCT00004999
Drug: Lamivudine/Zidovudine
RxNorm normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02697591
Drug: INCAGN01876
RxNorm normalized name: Incagn01876
DrugBank: Ragifilimab (DB18853)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
Trial: NCT00004999
Drug: Capravirine
RxNorm normalized name: Capravirine
DrugBank: Capravirine (DB08502)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02298088
Drug: Ticagrelor 180 mg
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor, 180 mg as early as possible after the index event and not \>24 h post event followed by 90 mg twice daily for 12 months.
Trial: NCT02298088
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 300 mg clopidogrel as early as possible after the index event and not \> 24h post event, followed by 75mg/day for 12 months.~For patients with \> 75 years the recommended load dose is 75 mg instead 300 mg.
Trial: NCT02258906
Drug: ulinastatin
RxNorm normalized name: ulinastatin
DrugBank: Ulinastatin (DB12038)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02078596
Drug: Divalproex
RxNorm normalized name: DIVALPROEX
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each
Trial: NCT00004999
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03001323
Drug: Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR \<30 ml/hr.~Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.~Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.~Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above.
Trial: NCT00701103
Drug: Dalotuzumab
RxNorm normalized name: DALOTUZUMAB
DrugBank: Dalotuzumab (DB11840)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT00718523
Drug: AMG 479
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
Trial: NCT00877539
Drug: PF-03526299
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled, two doses 4 hours apart
Trial: NCT00877539
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Inhaled
Trial: NCT02297425
Drug: PF-06459988
RxNorm normalized name: PF-06459988
DrugBank: PF-06459988 (DB14768)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients
Trial: NCT04319926
Drug: lidocaine topical system 1.8%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One topical system is applied to the subject's back for 12 hours.
Trial: NCT04319926
Drug: lidocaine patch 5%
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One generic lidocaine patch is applied to the subject's back for 12 hours.
Trial: NCT00076310
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m\^2 IV repeated every 21 days.
Trial: NCT00076310
Drug: OSI-774
RxNorm normalized name: OSI-461
DrugBank: OSI-461 (DB05415)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.
Trial: NCT00076310
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m\^2 IV every 21 days.
Trial: NCT01541072
Drug: Pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation
Trial: NCT01541072
Drug: Filgrastim
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils \>= 0.5 G/L)
Trial: NCT01139346
Drug: darinaparsin
RxNorm normalized name: darinaparsin
DrugBank: Darinaparsin (DB06179)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
Trial: NCT02080364
Drug: Azeliragon
RxNorm normalized name: Azeliragon
DrugBank: Azeliragon (DB12689)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azeliragon 5mg administered orally, once daily for 18 months
Trial: NCT00398047
Drug: Azacitadine and Hematopoietic Growth Factors
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Azacitadine and Hematopoietic Growth Factors
Trial: NCT00939588
Drug: Aliskiren/ Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00939588
Drug: Telmisartan/ Ramipril
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01758614
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: all participants in this group will be given medical therapy including Aspirin 100mg per day or clopidogrel 75mg per day
Trial: NCT01758614
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03964259
Drug: Intravenous fluids
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of post HDMTX intravenous fluids (IVF)
Trial: NCT00833404
Drug: Nicotine transdermal patch
RxNorm normalized name: MENTHOL 0.3 g in 100 TOPICAL PATCH [Aroamas Cot Nicotine Transdermal Patches]
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
Trial: NCT01568112
Drug: BG00012 (dimethyl fumarate)
RxNorm normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
Trial: NCT01568112
Drug: ASA
RxNorm normalized name: ASA
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 325 mg microcoated aspirin (ASA)
Trial: NCT00784589
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
Trial: NCT00303472
Drug: Romiplostim
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00457288
Drug: TF 002
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00624832
Drug: Xolair
RxNorm normalized name: Xolair
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;
Trial: NCT01737879
Drug: Peginesatide
RxNorm normalized name: Peginesatide
DrugBank: Peginesatide (DB08894)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants will receive peginesatide for the first 24 weeks.
Trial: NCT01737879
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All participants converted to epoetin alfa at week 25 for a total of 32 weeks
Trial: NCT02797860
Drug: Rocuronium
RxNorm normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparison of onset time and duration of rocuronium using Train of Four watch
Trial: NCT00000332
Drug: Nimodipine
RxNorm normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04204304
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ISO
Trial: NCT00638092
Drug: sodium iodide
RxNorm normalized name: Sodium Iodide
DrugBank: Sodium iodide (DB11119)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
Trial: NCT00638092
Drug: Sodium Chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
Trial: NCT00407342
Drug: Alefacept (drug)
DrugBank: Alefacept (DB00092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: alefaceptgiven iv
Trial: NCT06188325
Drug: Eliglustat
RxNorm normalized name: Eliglustat
DrugBank: Eliglustat (DB09039)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form:Capsule-Route of administration:Oral
Trial: NCT01310582
Drug: Desflurane
RxNorm normalized name: Desflurane
DrugBank: Desflurane (DB01189)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01310582
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01269099
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: control group (No-PCA group)
Trial: NCT03181685
Drug: Progesterone 25 MG subcutaneous
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A single subcutaneous administration per day from the day of oocyte retrieval
Trial: NCT03181685
Drug: Micronized progesterone 200 MG
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 vaginal administrations per day from the day of oocyte retrieval
Trial: NCT03181685
Drug: Cetrorelix Acetate
RxNorm normalized name: Cetrorelix Acetate
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhibition of Luteinizing Hormone (LH) premature surge during COS
Trial: NCT02217852
Drug: Nitrendipine
RxNorm normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.